Maplight Therapeutics (NASDAQ:MPLT) Hits New 12-Month High – Here’s Why

Maplight Therapeutics, Inc. (NASDAQ:MPLT) reached a new 52-week high during trading on Thursday . The company traded as high as $21.40 and last traded at $20.41, with a volume of 377255 shares. The stock had previously closed at $18.85.

Analysts Set New Price Targets

Several research firms have weighed in on MPLT. Zacks Research upgraded Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Leerink Partners started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price target on the stock. Morgan Stanley assumed coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target on the stock. Finally, Wall Street Zen lowered Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $31.00.

Maplight Therapeutics Stock Performance

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.